Dual-functional liposome for tumor targeting and overcoming multidrug resistance in hepatocellular carcinoma cells

Biomaterials

Volumn 33, Issue 29, 2012, Pages 7103-7114

  Zhang, Xinxin ^a   Guo, Shiyan ^a   Fan, Rong ^a   Yu, Miaorong ^a   Li, Feifei ^a   Zhu, Chunliu ^a   Gan, Yong ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Dual functional liposome; Galactosyl conjugated pluronic P123; Hepatocellular carcinoma; Mitoxantrone; Multidrug resistance; Tumor targeting

Indexed keywords

HEPATOCELLULAR CARCINOMA; MITOXANTRONE; MULTIDRUG RESISTANCE; PLURONICS; TUMOR TARGETING;

BIOCHEMISTRY; CYTOLOGY; ENCAPSULATION; TUMORS;

CELLS;

BIOMATERIAL; BREAST CANCER RESISTANCE PROTEIN; CELL SURFACE RECEPTOR; COPOLYMER; GALACTOSE; GALACTOSYL CONJUGATED PLURONIC P123; LIPOSOME; MACROGOL; MITOXANTRONE; NANOMATERIAL; POLOXAMER; POLY(PROPYLENE OXIDE); POLYMER; PROPYLENE OXIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CARCINOMA CELL; CELL VIABILITY; CHEMICAL MODIFICATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SELECTIVITY; DRUG TARGETING; DRUG TRANSPORT; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; LIPOSOMAL DELIVERY; LIVER CELL CARCINOMA; MALE; MEAN RESIDENCE TIME; MOUSE; MULTIDRUG RESISTANCE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; TRANSMISSION ELECTRON MICROSCOPY; TUMOR XENOGRAFT; ZETA POTENTIAL;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; HUMANS; LIPOSOMES; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MITOXANTRONE; NEOPLASM TRANSPLANTATION; NEOPLASMS; POLYMERS; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

MUS; RATTUS;

EID: 84864301079     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.06.048     Document Type: Article

References (49)

1. Renugalakshmi A., Vinothkumar T.S., Kandaswamy D. Nanodrug delivery systems in dentistry: a review on current status and future perspectives. Curr Drug Deliv 2011, 8:586-594.
2. Hu C.M., Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem Pharmacol 2012, 83:1104-1111.
3. Song X.R., Zheng Y., He G., Yang L., Luo Y.F., He Z.Y., et al. Development of PLGA nanoparticles simultaneously loaded with vincristine and verapamil for treatment of hepatocellular carcinoma. J Pharm Sci 2010, 99:4874-4879.
4. Sun Z., Zhao Z., Li G., Dong S., Huang Z., Ye L., et al. Relevance of two genes in the multidrug resistance of hepatocellular carcinoma: in vivo and clinical studies. Tumori 2010, 96:90-96.
5. Li G., Chen X., Wang Q., Xu Z., Zhang W., Ye L. The roles of four multi-drug resistance proteins in hepatocellular carcinoma multidrug resistance. J Huazhong Univ Sci Technolog Med Sci 2007, 27:173-175.
6. Patil Y., Sadhukha T., Ma L., Panyam J. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Release 2009, 136:21-29.
7. Wu Y., Lu Y.H., Lee A., Pan X.G., Yang X.J., Zhao X.B., et al. Reversal of multidrug resistance by transferring-conjugated liposomes co-encapsulating doxorubicin and verapamil. J Pharm Pharmaceut Sci 2007, 10:350-357.
8. Li X., Li P., Zhang Y., Zhou Y., Chen X., Huang Y., et al. Novel mixed polymeric micelles for enhancing delivery of anticancer drug and overcoming multidrug resistance in tumor cell lines simultaneously. Pharm Res 2010, 27:1498-1511.
9. Zhang W., Shi Y., Chen Y.Z., Yu S.Y., Hao J.G., Luo J.Q., et al. Enhanced antitumor efficacy by paclitaxel-loaded pluronic P123/127 mixed micelles against non-small cell lung cancer based on passive tumor targeting and modulation of drug resistance. Eur J Pharm Biopharm 2010, 75:341-353.
10. Jabr-Milane L.S., van Vlerken L.E., Yadav S., Amiji M.M. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev 2008, 34:592-602.
11. Li B., Xu H., Li Z., Yao M., Xie M., Shen H., et al. Bypassing multidrug resistance in human breast cancer cells with lipid/polymer particle assemblies. Int J Nanomedicine 2012, 7:187-197.
12. Drori S., Eytan G.D., Assaraf Y.G. Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability. Eur J Biochem 1995, 228:1020-1029.
13. Wang F., Zhang D., Zhang Q., Chen Y., Zheng D., Hao L., et al. Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel-polymer micelles to overcome multi-drug resistance. Biomaterials 2011, 32:9444-9456.
14. Holan V., Chudickova M., Trosan P., Svobodova E., Krulova M., Kubinova S., et al. Cyclosporine A-loaded and stem cell-seeded electrospun nanofibers for cell-based therapy and local immunosuppression. J Control Release 2011, 156:406-412.
15. Pennock G.D., Dalton W.S., Roeske W.R., Appleton C.P., Mosley K., Plezia P., et al. Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst 1991, 83:105-110.
16. Batrakova E.V., Li S., Li Y.L., Alakhov V.Y., Elmquist W.F., Kabanov A.V. Ditribution kinetics of a micelle-forming block copolymer pluronic P85. J Control Release 2004, 100:389-397.
17. Pec E.A., Wout Z.G., Johnston T.P. Biological activity of urease formulated in poloxamer 407 after intraperitoneal injection in the rat. J Pharm Sci 1992, 81:626-630.
18. Cheng J., Wang J., Chen B., Xia G., Cai X., Liu R., et al. A promising strategy for overcoming MDR in tumor by magnetic iron oxide nanoparticles co-loaded with daunorubicin and 5-bromotetrandrin. Int J Nanomedicine 2011, 6:2123-2131.
19. Batrakova E.V., Li S., Li Y., Alakhov V.Y., Kabanov A.V. Effect of pluronic P85 on ATPase activity of drug efflux transporters. Pharm Res 2004, 21:2226-2233.
20. Yamagata T., Morishita M., Kusuhara H., Takayama K., Benameur H., Sugiyama Y. Characterization of the inhibition of breast cancer resistance protein-mediated efflux of mitoxantrone by pharmaceutical excipients. Int J Pharm 2009, 370:216-219.
21. Wu D.Q., Lu B., Chang C., Chen C.S., Wang T., Zhang Y.Y., et al. Galactosylated flurescent labeled micelles as a liver targeting drug carrier. Biomaterials 2009, 30:1363-1371.
22. Yang R., Meng F., Ma S., Huang F., Liu H., Zhong Z. Galactose-decorated cross-linked biodegradable poly(ethylene glycol)-b-poly(e{open}-caprolactone) block copolymer micelles for enhanced hepatoma-targeting delivery of paclitaxel. Biomacromolecules 2011, 12:3047-3055.
23. Wei W., Yue Z.G., Qu J.B., Yue H., Su Z.G., Ma G.H. Galactosylated nanocrystallites of insoluble anticancer drug for liver-targeting therapy: an in vitro evaluation. Nanomedicine 2010, 5:589-596.
24. Fallon R.J., Schwartz A.L. Receptor-mediated delivery of drugs to hepatocytes. Adv Drug Deliv Rev 1989, 4:49-63.
25. Sonoke S., Ueda T., Fujiwara K., Kuwabara K., Yano J. Galactose-modified cationic liposomes as a liver-targeting delivery system for small interfering RNA. Biol Pharm Bull 2011, 34:1338-1342.
26. Huang S.J., Sun T.H., Feng T.H., Sung K.H., Lui W.L., Wang L.F. Folate-mediated chondroitin sulfate-pluronic_127 nanogels as a drug carrier. Eur J Pharm Sci 2009, 38:64-73.
27. Juszynski M.D., Flowers H.M. Studies on the Koenigs-Knorr reaction: part II. Synthesis of an α-L-linked disaccharide from tri-o-benzyl-α-L-fucopyranosyl bromide. Carbohyd Res 1971, 18:219-226.
28. Michal T.K., John F., Dali Y., Krystof S.B. Convection-enhanced delivery of liposmes to primate brain. Liposomes, part G. Methods in enzymology 2009, 351-352. Elsevier, USA. N. Düzgünes (Ed.).
29. Rudra A., Deepa R.M., Ghosh M.K., Ghosh S., Mukherjee B. Doxorubicin-loaded phosphatidylethanolamine-conjugated nanoliposomes: in vitro characterization and their accumulation in liver, kidneys, and lungs in rats. Int J Nanomedicine 2010, 5:811-823.
30. Pick A., Klinkhammer W., Wiese M. Specific inhibitors of the breast cancer resistance protein (BCRP). Chem Med Chem 2010, 5:1498-1505.
31. Houghton P., Fang R., Techatanawat I., Steventon G., Hylands P.J., Lee C.C. The sulphorhodamine (SRB) assay and other approaches to testing plant extracts and derived compounds for activities related to reputed anticancer activity. Methods 2007, 42:377-387.
32. Nicole Y.M., Wei C., Victor C., Angelo R., Paul D.S., Amir G. Real time in vivo non-invasive optical imaging using near-infrared fluorescent quantum dots. Acad Radiol 2005, 12:313-323.
33. Christian D.A., Garbuzenko O.B., Minko T., Discher D.E. Polymer vesicles with a red cell-like surface charge: microvascular imaging and in vivo tracking with near-infrared fluorescence. Macromol Rapid Commun 2010, 31:135-141.
34. Michaelis M., Zimmer A., Handjou N., Cinatl J., Cinatl J. Increased systemic efficacy of aphidicolin encapsulated in liposomes. Oncol Rep 2005, 13:157-160.
35. Lo A., Lin C.T., Wu H.C. Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery. Mol Cancer Ther 2008, 7:579-589.
36. Alvarez-Lorenzo C., Sosnik A., Concheiro A. PEO-PPO block copolymers for passive micellar targeting and overcoming multidrug resistance in cancer therapy. Curr Drug Targets 2011, 12:1112-1130.
37. Mamot C., Drummond D.C., Hong K., Kirpotin D.B., Park J.W. Liposome-based approaches to overcome anticancer drug resistance. Drug Resist Update 2003, 6:271-279.
38. Yik J.H., Saxena A., Weigel P.H. The minor subunit splice variants, H2b and H2c, of the human asialoglycoprotein receptor are present with the major subunit H1 in different hetoro-oligomeric receptor complexes. J Biol Chem 2002, 277:23076-23083.
39. Wang Y.J., Jiang G.Q., Qiu T.T., Ding F.X. Preparation and evaluation of paclitaxel-loaded nanoparticle incorporated with galactose-carrying polymer for hepatocyte targeted delivery. Drug Dev Ind Pharm 2011, 29:1-8.
40. Alakhvoa D.Y., Rapoport N.Y., Batrakova E.V., Timoshin A.A., Li S., Nicholls D., et al. Differential metabolic responses to pluronic in MDR and non-MDR cells: a novel pathway of chemosensitization of drug resistant cancers. J Control Release 2010, 142:89-100.
41. Han M., Diao Y.Y., Jiang H.L., Ying X.Y., Chen D.W., Liang W.Q., et al. Molecular mechanism study of chemosensitization of doxorubicin-resistant human myelogenous leukemia cells induced by a composite polymer micelle. Int J Pharm 2011, 420:404-411.
42. Yoh Z., Takahiko F., Seiichi Y., Hiroyuki T., Takashi T., Tetsuo O., et al. Histological and culture studies with respect to ABCG2 expression support the existence of a cancer cell hierarchy in human hepatocellular carcinoma. Am J Pathol 2007, 170:1750-1762.
43. Song C.K., Balakrishnan P., Shim C.K., Chung S.J., Kim D.D. Enhanced in vitro cellular uptake of P-gp substrate by poloxamer-modified liposomes (PMLs) in MDR cancer cells. J Microencapsul 2011, 28:575-581.
44. Kabanov A.V., Batrakova E.V., Alakhov V.Y. Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J Control Release 2002, 82:189-212.
45. Ueda K., Kawaguchi Y., Iwakawa S. Effect of oxyethylene numbers on the pharmacokinetics of menatetrenone incorporated in oil-in-water lipid emulsions prepared with polyoxyethylene-polyoxypropylene block copolymers and soybean oil in rats. Biol Pharm Bull 2008, 31:2283-2287.
46. Maruyama K. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv Drug Deliv Rev 2011, 63:161-169.
47. Tiourina O., Sharf T., Balkina A., Ollivon M., Selischeva A., Sorokoumova G., et al. Interaction of the water-soluble protein aprotinin with liposomes: gel-filtration, turbidity studies, and 31P NMR studies. J Liposome Res 2003, 13:213-229.
48. Wang Y.Z., Li Y.J., Zhang L.J., Fang X.L. Pharmacokinetics and biodistribution of paclitaxel-loaded pluronic P105 polymeric micelles. Arch Pharm Res 2008, 31:530-538.
49. Han L.M., Guo J., Zhang L.J., Wang Q.S., Fang X.L. Pharmacokinetics and biodistribution of polymeric micelles of paclitaxel. Acta Pharmacol Sin 2006, 27:747-753.